Business strategy is the set of deliberate choices a firm makes about where to compete, how to win, and what not to do. That last part is the one most leaders skip. Strategy without exclusion is just a wishlist.

At its core, a business strategy translates organizational purpose into prioritized action. It answers three questions simultaneously: Which markets and customer segments deserve our focus? What distinctive capabilities will we deploy to serve them better than alternatives? And what activities will we deliberately avoid — because pursuing them would dilute what makes us effective?

This is different from operational planning, which asks how to execute efficiently within defined parameters. Strategy defines the parameters themselves.

Where Business Strategy Operates

Strategy functions at multiple organizational levels, and conflating them is one of the most common sources of strategic confusion.

Corporate strategy operates at the enterprise level: which businesses should we be in? This is the terrain of portfolio decisions, capital allocation, and M&A logic. A life sciences holding company deciding whether to invest in diagnostics versus drug delivery is making a corporate strategy call.

Business unit strategy operates one level down: given that we are in this market, how do we win? This is where competitive positioning, go-to-market design, and value proposition definition live. A bioprocessing equipment supplier deciding whether to compete on process performance versus supply chain flexibility is making a business unit strategy decision.

Functional strategy operates at the department level: how does this function serve the broader competitive position? A commercial team’s sales coverage model, a regulatory team’s submission sequencing, a manufacturing team’s capacity investment timeline — these are functional strategies. They matter most when they are explicitly designed to reinforce the business unit strategy above them.

Most strategic plans that fail do so because they operate at only one level while assuming alignment across all three. Corporate allocates capital based on one set of priorities; business units design go-to-market around a different set; functional teams execute against neither.

Growth Strategy: The Most Misused Term in Business

Organizations routinely describe revenue objectives as growth strategies. They are not. “Grow revenue by 15%” is an objective. Strategy is the logic for how the company will achieve it in a way that competitors cannot easily replicate.

Growth paths fall into two categories:

Organic growth comes from the firm’s own capabilities — new product development, expanded commercial coverage, deeper penetration of existing accounts, or entry into adjacent market segments. It is slower to materialize but builds proprietary capability.

Inorganic growth comes from acquiring capabilities, customers, or market position externally — through M&A, licensing, or distribution partnerships. It is faster but carries integration risk and does not build internal muscle.

Neither is inherently superior. The strategic question is: given our current capability profile and competitive position, which growth path closes our most important gaps fastest? That question requires honest assessment of what the firm can actually do well, not just what leadership aspires to do.

What Strategy Is Not

Clarity about what strategy excludes is as important as what it includes. Cost-cutting programs are not strategies — they are operational efficiency measures. Marketing slogans are not strategies — they are communication tools. Annual planning decks are not strategies — they are resource allocation documents.

A real strategy has a logic that explains why the chosen approach will produce a result that alternatives would not. It is asymmetric: it bets that the firm’s specific combination of capabilities, market position, and execution discipline will produce an outcome competitors cannot match without substantial cost or delay.

In life sciences, where market access is narrow, regulatory requirements are exacting, and customer relationships take years to build, that asymmetry tends to come from depth of domain expertise, proximity to end users, and speed of technical problem-solving — not from scale or price.

The Role of Strategic Discipline

Strategy is as much about what an organization stops doing as what it starts. The firms that execute best against a strategy are typically those that have built internal mechanisms — resource allocation, incentive structures, planning gates — that make it difficult to drift back toward undifferentiated activity.

This is harder than it sounds. Markets present opportunities constantly. Customer requests pull firms in directions that feel reasonable in isolation but fragment strategic focus over time. The discipline required to say no to adjacent opportunities is, in practice, one of the rarest organizational capabilities.

MKA Strategic Implication

Mid-market life sciences companies most often struggle not with identifying the right strategy but with maintaining the discipline to execute it exclusively. The default behavior under competitive pressure is to expand scope — to add customer segments, service lines, or geographies — without adding the capabilities required to serve them well. This is how firms lose the strategic focus that made them effective in the first place. Periodic strategy reviews should explicitly ask: what did we say no to, and was that the right call?